Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.58. Xtant Medical shares last traded at $0.55, with a volume of 7,882 shares changing hands.

Wall Street Analyst Weigh In

Separately, Craig Hallum set a $1.50 price target on shares of Xtant Medical and gave the stock a “buy” rating in a research note on Friday.

Xtant Medical Stock Performance

The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.01 and a current ratio of 2.44. The stock has a market capitalization of $71.81 million, a PE ratio of -27.56 and a beta of 0.35.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings results on Thursday, August 8th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The firm had revenue of $29.94 million for the quarter. Xtant Medical had a negative net margin of 3.00% and a negative return on equity of 6.71%.

Institutional Trading of Xtant Medical

An institutional investor recently bought a new position in Xtant Medical stock. Juniper Investment Company LLC acquired a new stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 348,399 shares of the medical device company’s stock, valued at approximately $408,000. Xtant Medical makes up approximately 0.2% of Juniper Investment Company LLC’s holdings, making the stock its 10th largest position. Juniper Investment Company LLC owned about 0.27% of Xtant Medical as of its most recent SEC filing. 69.33% of the stock is currently owned by institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.